Abstract. There is an ongoing search for plant-derived diterpenes, especially for diterpenes with anti-inflammatory activity that also have anti-proliferative effects on human cancer cells. A cyathane-type diterpene, Sarcodonin G (SG), isolated from the mushroom Sarcodon scabrosus and already reported to have anti-inflammatory activity, inhibited proliferation of HeLa cells to the greatest extent among 4 cyathane diterpenes tested. SG showed an IC 50 (50% inhibition concentration) of 20 μM, estimated by MTT assay 2 days after culture of cells with the chemical. SG treatment of HeLa cells resulted in dose-dependent generation of apoptotic events such as DNA-laddering (≤100 μM). Moreover, SG-treated HeLa cells showed activation of caspase-3 and caspase-9 and increase of Bax/Bcl-2 ratios, as analyzed by Western blot analysis. The anti-proliferative effects of SG treatment on HeLa cells were lessened by a caspase inhibitor, Z-VAD-FMK. SG also showed anti-proliferative effects toward 5 other human cancer cell lines with IC 50 values of 20-40 μM. Because of these anti-proliferative effects via possible caspase activation, SG holds promise of being a novel anti-proliferative agent deserving further investigation.
Introduction
Plants are thought to contain chemical compounds that inhibit proliferation of cancer-derived cells in vitro, and many attempts have been made to isolate anti-cancer drugs from plants. For example, the diterpene paclitaxel (Taxol ® ) is a well-known anti-proliferative agent isolated from Taxus brevifolia (1, 2) . Various groups conducted research on other diterpene species with the aim of finding more effective agents for the treatment of cancer (3) .
Instead of searching for anti-proliferative compounds from plants in the first place, it would be possible to investigate known anti-inflammatory compounds as possible inhibitors of cell proliferation and tumor promotion activity (4, 5) . We recently found that SG, one of the diterpenes of the cyathane type that has a tricyclic carbon skeleton, suppressed inflammation induced by a tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA) (4, 6) . SG was first isolated from the mushroom Sarcodon scabrosus by Shibata et al and synthesized by Edward et al (7, 8) . There have been only a few reports that diterpenes from mushrooms have anti-proliferative activity on cancer-derived cells and therefore could be an anti-cancer drug (9) . It is of great interest to us whether SG has the ability to inhibit cell proliferation of cancer-derived cells.
There are cytotoxic drugs that act primarily by inducing apoptosis in sensitive target cells (10) . Preliminarily data suggests apoptosis occurs in SG-treated HeLa cells, as determined by transmission electron microscopy showing chromatin condensation, marginal convergency and fragmentation (11) . In the present study, we first compared the antiproliferative effect of SG with that of other 3 cyathane diterpenes from Sarcodon scabrosus in HeLa cells. We further confirmed that the anti-proliferative effect of SG was actually induced via the apoptotic signaling pathway and elucidated the molecular mechanisms of SG-induced apoptotic events. We also examined whether SG inhibits cell proliferation of 5 other cancer cell lines in addition to HeLa cells.
Materials and methods
Agents. Cyathane diterpenes tested were isolated from the fruiting body of Sarcodon scabrosus. Dry fruiting bodies of S. scabrosus (1.3 kg) were extracted with methylene chloride and the extract was subjected to silica gel chromtography with ethyl acetate/hexane mixtures by 10% stepwise elution to give 20, 50, 60 and 70% ethyl acetate eluates.
The 20% ethyl acetate/hexane eluate was further purified with ODS column chromatography with 90% methanol/ water to give sarcodonin E (19-O-acetyl-sarcodonin A, 60 mg) (7, 12 The 50% ethyl acetate/hexane eluate was further subjected to silica gel chromatography with acetone/chloroform mixtures to give a 10% acetone/chloroform eluate. The eluate was purified by ODS column chromatography with 70% methanol/ water, followed by purification by HPLC with an ODS column to give sarcodonin Q (2-oxo-sarcodonin B, 14 mg) ( The 60% and 70% ethyl acetate/hexane eluates were further purified by column chromatography on silica gel with acetone/chloroform mixtures followed by ODS column chromatography to give sarcodonin G (210 mg) (7).
The structures of the four cyathane diterpene compounds were elucidated as shown in Fig. 1 on the basis of spectral data. Each of the isolated cyathane diterpenes was dissolved in dimethyl sulfoxide (DMSO) (Wako, Osaka, Japan). Anticancer drugs used were as follows: 5-fluorouracil (5-FU) (F6627, Sigma, St. Louis, MO, USA) and cis-diammineplatinum (II) dichloride (cisplatin) (076K1697, Sigma). As a caspase inhibitor, Z-VAD-FMK (G7232, Promega Corp., Madison, WI, USA) was used. Unless specifically stated, other reagents were purchased from Wako Pure Chemical Industry (Osaka, Japan).
Cells and culture conditions. The following human cell lines were used: HeLa (a cervical cancer cell line) (13), HEC-1 (an endometrial adenocarcinoma cell line) (15), HOC-21 (an ovarian serous cystadenocarcinoma cell line) (15), U251SP (a glioma cell line) (14) , MM-1CB (a melanoma cell line) (15) and HMV-1 (a melanoma cell line) (15) . Cells were cultured in Eagle's minimal essential medium (EMEM), containing 10% (v/v) calf serum (Invitrogen, Carlsbad, CA, USA) and antibiotics (100 μg/ml of streptomycin, Meiji Seika, Tokyo, Japan) and 100 U/ml of penicillin G (Meiji Seika), at 37˚C in a humidified atmosphere containing 5% CO 2 .
Measurement of cell viability. Cell viability was estimated by the MTT assay as previously described (16) . Briefly, logarithmically proliferating cells were plated onto 96-well plates (Asahi Glass, Tokyo, Japan) (1x10 4 cells/well) with the medium containing the test compounds at the indicated doses, followed by culture for 2 days. After the culture, the activity of mitochondrial succinic dehydrogenase was measured by further incubation of the cells with 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma) for 4 h, followed by measurement of absorbance at 570 nm with a reference wavelength at 655 nm. Cell survival was calculated from absorbance and presented as a percentage of the surviving cells.
Cell proliferation numbers per one dish were estimated principally according to the method described previously (14) . Briefly, cells were seeded at 1x10 5 cells per 60-mm dish (Corning, NY, USA), and 1 day later were replenished with medium containing the indicated agents. After the replenishment, cells were cultured during the indicated days until 7 days after the seeding. Changes of medium with and without agents were carried out every other day. Viable cells were determined by the Trypan-blue dye exclusion test and counted with a hemocytometer.
Measurement of cell-cycle phase distribution. Cell-cycle phase distributions were measured as described previously (16) . Briefly, cells were cultured in 60-mm dishes with SG (≤100 μM) for 24 h, followed by trypsinization, washed three times with PBS and fixed in 70% cold ethanol. After fixation, cells were suspended in staining solution (50 μg/ml of propidium iodide (PI), 4 mM sodium citrate, 0.2 mg/ml RNase A, and 0.1% Triton X-100) for 10 min on ice. NaCl was then added to the solution to a final concentration of 0.15 M. The stained cell samples were analyzed using a FACScan instrument (Becton-Dickinson, NJ, USA). Cells undergoing apoptosis were evaluated as a percentage of cells with a sub-G 1 population. The fraction of sub-G 1 population was calculated with computer software, CellQuest (BectonDickinson). Cell-cycle phase distribution measurements were repeated in three different cultures.
DNA fragmentation analysis. Apoptotic DNA fragments were detected as previously described (17) . Briefly, SG (≤100 μM)-treated and mock-treated cells were cultured for 48 h, and then lysed for 3 h at 37˚C in a solution containing 50 mM Tris-HCl (pH 8.0), 2 mM EDTA, 1% SDS and 100 μg/ml proteinase K. Following the addition of one-tenth volume of 3 M sodium acetate, nucleotides were extracted with phenol/ chloroform and then with chloroform alone. High-molecular weight DNA was precipitated by addition of 2-propanol by seven-tenth volume, followed by centrifugation at 15,000 rpm for 5 sec at room temperature. Low-molecular weight DNA was recovered from the supernatant by centrifugation after incubation overnight at -20˚C, re-suspended in 10 mM Tris-HCl (pH 8.0), 1 mM EDTA and 50 μg/ml of DNase-free RNase A and then incubated for 3 h at 37˚C. Samples were applied to 1.5% agarose gel containing 0.5 μg/ml ethidium bromide, and electrophoresed in 90 mM Tris-borate (pH 8.0) and 2 mM EDTA at 100 V for 3 h. DNA ladders were photographed under UV illumination.
Immunoblot analysis. Immunoblot analysis was carried out as described previously (18) . After SG treatment for 24 h, cells were solubilized in 1X SDS sampling buffer. The whole cell lysates were separated by electrophoresis on 12% (w/v) SDS-PAGE. Active forms of caspase-3 and caspase-9 proteins were detected using rabbit anti-cleaved caspase-3 antibody (2305-PC-020, Trevigen, MD, USA) (1:800 dilution) and mouse anti-human caspase-9 antibody (MAB8301, R&D, Minneapolis, MN, USA) (1:1000 dilution), respectively. The latter antibody detects non-cleaved and cleaved caspase-9. Bax and Bcl-2 proteins were detected using anti-mouse Bax monoclonal antibody (SC-7480, Santa Cruz Biotechnology, USA) (1:300 dilution) and anti-mouse Bcl-2 monoclonal antibody (Santa Cruz Biotechnology) (SC-7382, 1:300 dilution), respectively. The antigen-antibody complexes were detected by anti-rabbit IgG (NA934V, GE, Healthcare, UK) and anti-mouse IgG (NA931V, Amersham Biosciences, Buckinghamshire, UK), followed by visualization using the ECL system (GE). Amounts of actin were also analyzed by mouse anti-actin antibody (NA931V, Illkirch, Cedex, France) (1:20000 dilution) as the loading control. The intensities of the protein signals were quantified using Multi Gauge Ver2.2 image analyzing software (Fuji Foto Film, Tokyo, Japan) and expressed as a relative value to that of actin.
Other conditions. Values were expressed as means of those obtained from more than two independent experiments, unless specifically stated otherwise. Mock treatment was performed under the solvent conditions containing 0.1% DMSO. Statistical analysis was performed using the Student's t-test with StatView software (Version 4.5; Abacus Concepts, Berkeley, CA, USA), as previously described (18) .
Results

Inhibition of viability of HeLa cells by SG.
The cytotoxic potential of 4 isolated diterpenes (Fig. 1) was tested by the MTT assay after culture of HeLa cells in the presence of the chemical compounds for two days. Both the SE and SQ treatment resulted in only a slight decrease in cell viability among the doses tested (≤100 μM) (Fig. 2) . NeoSH treatment resulted in the same extent of cell viability inhibition as that of the control 5-FU (Fig. 2) . However, SG treatment showed dose-dependent inhibition to a greater extent than 5-FU, although the inhibition was not so strong as that of cisplatin (Fig. 2) . The IC 50 , the concentration to inhibit the proliferation of HeLa cells by 50%, of SG, 5-FU and cisplatin was 18 μM, >100 μM and 3.0 μM, respectively.
The anti-proliferative activity of SG was also evaluated in comparison with that of cisplatin by a cell proliferation test. After 1-day exposure to SG at a concentration in excess of 10 μM, the proliferation of HeLa cells was inhibited; the extent of the inhibition was less than that after 1-day exposure to cisplatin at the same concentration (Fig. 3) . However, when HeLa cells were exposed for 2 days to SG at a concentration in excess of 10 μM, the proliferation was inhibited to the same extent as that after 1-day exposure to cisplatin at the same concentration (Fig. 3) .
Apoptotic events in SG-treated HeLa cells.
The cell cycle distribution in HeLa cells was examined by flow cytometric analysis after PI staining. A distinct increase in the population of cells in the sub-G 1 phase (apoptotic fraction) was observed in the cells treated with 100 μM SG for 1 day (Fig. 4A) . The increase was dose-dependent ≤100 μM SG (Fig. 4B) . These results suggested the induction of apoptosis in SG-treated HeLa cells. To confirm that SG causes apoptosis, the fragmentation status of genomic DNA was examined in HeLa cells treated with the compound. Short fragments of DNA were observed in cells treated with 50 and 100 μM of SG (Fig. 5A) , although the distinct fragmentation was observed after treatment with cisplatin at concentrations higher than 25 μM (Fig. 5B) .
Activation of caspases in SG-treated HeLa cells.
To elucidate the mechanisms of SG treatment-induced apoptosis in HeLa cells, we assessed the possible involvement of caspases, by detecting the active cleaved forms of caspase-3 and -9. Amounts of both active forms increased by a small extent after 1-day treatment with 50 μM SG (Fig. 6 ), but a 100 μM SG treatment resulted in more than 3-fold increase compared to the mock treatment (Fig. 6 ), similar to that with 50 μM cisplatin (Fig. 6A) , illustrating the functional relevance of caspase activation during SG treatment-induced apoptosis.
Suppression of SG treatment-induced cell death by Z-VAD-FMK in HeLa cells.
To evaluate caspase activation in SGtreated HeLa cells, the effect of a general caspase inhibitor, Z-VAD-FMK, on SG treatment-induced cell death was examined by combined treatment of the inhibitor with SG. The Z-VAD-FMK combination resulted in a slight increase of survival at 10 μM SG and a more pronounced increase at concentrations in excess of 50 μM SG (Fig. 7) . These results indicated that caspase activation was causally related to SG treatment-induced cell death, and that this finding is further evidence that SG treatment induces apoptosis in HeLa cells.
Increased ratios of Bax/Bcl-2 in SG-treated HeLa cells.
To further investigate the molecules involved in SG treatmentinduced apoptosis, we estimated amounts of Bax and Bcl-2 proteins, proteins involved in caspase induction, in HeLa cells treated with and without SG for 1 day. Western blot analysis showed that expression of the Bcl-2 protein decreased after SG treatment (50-100 μM) (Fig. 8A) and Bax/Bcl-2 protein ratios increased (Fig. 8B) , although the ratios decreased slightly after treatment with 10 μM SG. Thus, the Bax/Bcl-2 ratio correlated with apoptosis induced by higher than 50 μM SG in HeLa cells.
SG treatment-induced cell death in 5 other cancer cell lines and its suppression by Z-VAD-FMK.
As well as HeLa cells, 5 other human cancer cell lines (HOC-21, HEC-1, U251-SP, MM-1CB and HMV-1) were tested for their susceptibility to SG. Distinct inhibition of cell survival was observed after both 50 μM (Fig. 9A ) and 100 μM (Fig. 9B ) SG treatments in all cell lines, including HeLa cells (Fig. 7) , although MM-1CB cells were less susceptible to SG than the other 5 cell lines (Fig. 9) . Additionally, SG treatment-induced cell death was suppressed by Z-VAD-FMK in these 5 cell lines (Fig. 9) , as already observed in HeLa cells (Fig. 7) . Particularly, U251SP and HMV-1 cells treated with Z-VAD-FMK showed 2-fold higher survival levels than those treated with SG alone (Fig. 9) , suggesting sufficient recovery of survival by Z-VAD-FMK.
The results indicate that SG also induced apoptosis in these human cancer cell lines.
Discussion
Among 4 chemicals purified from Sarcodon scabrosus, SG seemed to exhibit the greatest inhibition of HeLa cell viability, estimated by the MTT assay ( Fig. 2 ) and cell proliferation (Fig. 3) analyses. The sensitivity of HeLa cells to SG was higher than that to 5-FU, but lower than that to cisplatin (Figs. 2 and 3 ). Some chemotherapeutic anticancer agents including 5-FU and cisplatin are known to induce apoptosis (19, 20) , as shown here by DNA fragmentation in cisplatin-treated HeLa cells (Fig. 5) . In the present study SG (at concentrations in excess of 50 μM) also induced apoptotic events in HeLa cells; increased population in apoptotic sub-G 1 fraction (Fig. 4) and DNA fragmentation (Fig. 5) . The mechanisms underlying the SG-induced apoptosis in HeLa cells were revealed by increased amounts of the active forms of caspases-3 and/or -9 (Fig. 6) . Activated caspase-9 is thought to cleave and to activate the other effector caspases such as caspase-3, leading to apoptotic events (21) . Thus, activation of caspase-3 and/ or -9 may be involved in SG-induced apoptosis. The causal relationship of SG-induced apoptosis and caspase activation was also confirmed by suppression of apoptosis in HeLa cells treated with a caspase inhibitor, Z-VAD-FMK, and SG (Fig. 7) .
Our data also demonstrated modulation of Bax and Bcl-2 in SG-treated HeLa cells (Fig. 8A ). Bax and Bcl-2 are proapoptotic and anti-apoptotic proteins, respectively (22) . The relative expression ratio of Bax versus Bcl-2 was reported to be correlated with 5-FU sensitivity in various cancer cell lines (23) . On the other hand, one of the intrinsic pathways of caspase activation is suggested to be up-regulation of the ratio of protein amounts of Bax versus Bcl-2 (23, 24) . In fact, this Bax/Bcl-2 ratio increased in SG (at concentrations in excess of 50 μM)-treated HeLa cells (Fig. 8B ). Therefore, it is possible that SG treatment (at concentrations in excess of 50 μM) induces caspase-mediated apoptosis in HeLa cells via modulation of Bax and Bcl-2.
The viability of 5 other cancer cell lines was decreased by SG treatment and the suppression of the SG effect was observed in combination with Z-VAD-FMK treatment (Fig. 9) . Thus, it seems likely that SG has a lethal effect on various cancer cells, at least those tested here, possibly via caspase activation.
SG treatment results in an anti-inflammatory effect on TPA-induced inflammation in mice (4, 6) . This effect was not affected by the combination treatment with Z-VAD-FMK (data not shown). Thus, Z-VAD-FM-sensitive caspases are not involved in the anti-inflammatory action of SG. There is growing interest in the elucidation of the biological functions of terpenes that are used as anticancer and anti-inflammatory agents (25) (26) (27) . Diterpenes, such as SG, may be useful starting points for the development of anticancer and anti-inflammatory chemotherapy through pursuing a thorough investigation of the molecular mechanisms underlying diterpene-induced apoptosis. 
